Automating
Immune Therapy Research
for demonstration purposes only; actual product may vary
Did you know that over 75% of immune therapies directly or indirectly act via the T cells?
T cells are the central players of the immune defense against many diseases including cancer.
We’re introducing a fully automated way to analyze T cells to enable immune therapy research to scale faster, more accurately, and at lower cost.
Market Opportunity
T‑cell-based therapies like CAR-T and TCR are among the fastest-expanding segments of immunotherapy that are expected to reach $15‑80 billion by the mid‑2030s, with double‑digit annual growth rates.
The Challenge:
Immunotherapies Need Better Tools
Immune diseases are everywhere: cancer, infections, allergies, and autoimmune disorders all involve the immune system. Immune therapies are emerging as powerful tools to treat them.
Yet immunotherapy R&D is slow, manual, and expensive. A single experiment can cost over $50K and still rely on outdated, labor-intensive methods.
Standardization is difficult and expensive. Manual protocols vary across labs, and even small differences in technique or timing can affect results, which results in slowing reproducibility and clinical translation.
100XBIO solves this with automation by bringing the efficiency and scalability of robotics and machine learning to immunology.
Our Solution
An Automated Platform for T-Cell Assays
Our robotic system automates over 90% of the workflow for cell-based immune assays, allowing to dramatically reduce manual labor, increase consistency, and accelerate research.
-
Up to 10-100x more data extracted from each biosample
-
ML-powered analysis for faster insight generation and reduced human errors
-
Designed for use in academic and industry labs
Key applications: cancer vaccines, CAR-T therapies, bispecific antibodies, autoimmune diseases, and other T-cell–driven conditions.